IBJNews

Lilly's Amyvid receives European approval

Back to TopCommentsE-mailPrintBookmark and Share

European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.

The Indianapolis-based drugmaker plans to make Amyvid available in parts of the European Union in the second quarter, after giving imaging centers time to prepare to receive orders. U.S. regulators approved Amyvid last spring.

The radioactive imaging agent binds to beta-amyloid plaques and causes them to show up on positron emission tomography, or PET, scans of a patient's brain. The presence of these plaques may help indicate that a patient with cognitive problems has Alzheimer's disease, although such a scan does not definitively show that.

Lilly said Tuesday that other neurological disorders, brain tumors and infections like HIV may cause the presence of plaque. It also can be found in older people with normal cognitive function.

The drugmaker has said Amyvid is one tool intended to help find the cause of a patient's cognitive decline, and it should be used in conjunction with a clinical exam. Doctors diagnose Alzheimer's disease by observing patients and administering physical and mental tests.

Researchers say the disease could be diagnosed sooner if they could detect the presence of amyloid plaques earlier.

Amyvid was developed by Avid Radiopharmaceuticals, which Eli Lilly bought for $300 million in 2010.

Alzheimer's disease is the most common form of dementia, a term for brain disorders that affect memory, judgment and other mental functions.

The European Committee for Medicinal Products for Human Use had recommended Amyvid's approval in October.

Lilly shares closed just shy of a 52-week high Tuesday, at $53.29 each.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT